Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PinnacleXon Sep 03, 2019 9:25am

97 Views

Post# 30089693

RE:RE:RE:Nasdaq listing

PinnacleX wrote:
SPCEO1 wrote: No, it is not an issue unless it falls below $2

juniper88 wrote: Is the application going to be impacted by the current low share price? I believe about $3.70 in USD.

are you for real or constantly spred false information? ITS already a problem

This is from nasdaq To qualify for listing on theNYSE, a company must have at least 400 shareholders, with at least 1.1 millionsharesavailable to the public and a market value of the publicsharesof at least $40 million. Eachstockmust have aminimumvalue of $4 at the time of listing

Bullboard Posts

Stockhouse DealRoom opens new Australian opportunities